BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 15663654)

  • 1. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
    el-Azhary RA; Bouwhuis SA
    Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
    Brennand S; Sutton VR; Biagi J; Trapani JA; Westerman D; McCormack CJ; Seymour JF; Kennedy G; Prince HM
    Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
    J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
    McGinnis KS; Shapiro M; Vittorio CC; Rook AH; Junkins-Hopkins JM
    Arch Dermatol; 2003 Jun; 139(6):771-5. PubMed ID: 12810509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hyperkeratotic and desquamative reaction in a patient with Sézary syndrome treated with bexarotene.
    Bagazgoitia L; Pérez-Carmona L; Ríos L; Muñoz E; Harto A; Jaén P
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):389-90. PubMed ID: 18269619
    [No Abstract]   [Full Text] [Related]  

  • 7. Bexarotene monotherapy for patients with refractory Sézary syndrome.
    Staib G; Scharffetter-Kochanek K
    Dermatol Clin; 2008 Jan; 26 Suppl 1():61-3. PubMed ID: 18405190
    [No Abstract]   [Full Text] [Related]  

  • 8. Bexarotene combination therapy for patients with Sézary syndrome.
    Ranki A
    Dermatol Clin; 2008 Jan; 26 Suppl 1():55-7. PubMed ID: 18405189
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.
    Bouwhuis SA; el-Azhary RA; McEvoy MT; Gibson LE; Habermann TM; Witzig TE; Pittelkow MR
    Int J Dermatol; 2002 Jun; 41(6):352-6. PubMed ID: 12100691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP; Levitan D; Fleischer AB
    J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
    Bagot M
    Dermatol Clin; 2008 Jan; 26 Suppl 1():27-9. PubMed ID: 18405184
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome and review of the literature.
    Sanli H; Akay BN; Ozcan M
    J Drugs Dermatol; 2010 Aug; 9(8):1014-6. PubMed ID: 20684154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
    Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
    Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The Sézary syndrome].
    Ferreira F; Correia TM; Callabro L; Andrade J
    Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
    Martin AG
    J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine.
    Richardson SK; Newton SB; Bach TL; Budgin JB; Benoit BM; Lin JH; Yoon JS; Wysocka M; Abrams CS; Rook AH
    Am J Hematol; 2007 Sep; 82(9):792-7. PubMed ID: 17546636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Juvenile mycosis fungoides treated with bexarotene and PUVA.
    Rodríguez-Vázquez M; García-Arpa M; González-García J
    Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
    McGinnis KS; Junkins-Hopkins JM; Crawford G; Shapiro M; Rook AH; Vittorio CC
    J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Extracorporeal photopheresis in the therapy of Sézary syndrome].
    Marschalkó M; Knobler R; Soós G; Berecz M; Pálóczy K; Rácz I
    Orv Hetil; 1993 Jun; 134(23):1253-7. PubMed ID: 8332344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-Sézary erythroderma evolving to Sézary syndrome. A report of seven cases.
    Buechner SA; Winkelmann RK
    Arch Dermatol; 1983 Apr; 119(4):285-91. PubMed ID: 6220677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.